Literature DB >> 23313306

Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems.

Yuko Kakuda1, Kenichi Harada, Seiko Sawada-Kitamura, Hiroko Ikeda, Yasunori Sato, Motoko Sasaki, Hirofumi Okafuji, Eishiro Mizukoshi, Shuichi Terasaki, Hajime Ohta, Satomi Kasashima, Atsuhiro Kawashima, Yasuharu Kaizaki, Shuichi Kaneko, Yasuni Nakanuma.   

Abstract

Recently, our research team proposed a new histologic staging and grading system for primary biliary cirrhosis (PBC) that takes into account necroinflammatory activity and histologic heterogeneity. The present study aimed to confirm the usefulness of the new evaluation system. A total of 152 liver biopsy specimens and clinical data (including outcomes in patients with PBC before treatment with ursodeoxycholic acid) were analyzed with respect to the new system. Staging was evaluated on the basis of 3 histologic components (fibrosis, bile duct loss, and deposition of orcein-positive granules), and grading was assessed on the basis of chronic cholangitis activity and hepatitis activity. Concurrently, the classical systems, that is, the Scheuer and Ludwig staging systems, were also assessed and compared with our new system. PBC cases showed different distributions in each stage of the 3 systems. The new staging and grading system reflected liver dysfunctions before specific treatment. This was on a par with the results obtained using the classical systems. Development of cirrhosis-related conditions correlated well with the new staging system compared with the 2 classical staging systems, and in particular, the amount of deposition of orcein-positive granules could reflect development of cirrhosis-related conditions (scores 0-1 versus scores 2-3 groups, P < .0001). In conclusion, the new PBC staging system was demonstrated to reflect clinicolaboratory features, and its progression was associated with the development of cirrhosis-related conditions.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23313306     DOI: 10.1016/j.humpath.2012.09.017

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

Review 2.  Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel.

Authors:  Jeanne M Horowitz; Sudhakar K Venkatesh; Richard L Ehman; Kartik Jhaveri; Patrick Kamath; Michael A Ohliger; Anthony E Samir; Alvin C Silva; Bachir Taouli; Michael S Torbenson; Michael L Wells; Benjamin Yeh; Frank H Miller
Journal:  Abdom Radiol (NY)       Date:  2017-08

3.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

4.  Anti-mitochondrial M2 antibody-positive autoimmune hepatitis.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Kazunori Fugo; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Takashi Kishimoto; Naoki Ishige
Journal:  Exp Ther Med       Date:  2015-08-20       Impact factor: 2.447

5.  The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases.

Authors:  Kazumichi Abe; Atsushi Takahashi; Yoshihiro Nozawa; Hiromichi Imaizumi; Manabu Hayashi; Ken Okai; Yukiko Kanno; Hiroshi Watanabe; Hiromasa Ohira
Journal:  Med Mol Morphol       Date:  2014-06-27       Impact factor: 2.309

6.  Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis.

Authors:  Manabu Hayashi; Kazumichi Abe; Masashi Fujita; Ken Okai; Atsushi Takahashi; Yoshihiro Nozawa; Hiromasa Ohira
Journal:  Med Mol Morphol       Date:  2018-01-29       Impact factor: 2.309

7.  Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis.

Authors:  Mio Kobayashi; Yuko Kakuda; Kenichi Harada; Yasunori Sato; Motoko Sasaki; Hiroko Ikeda; Mitsuhiro Terada; Munenori Mukai; Shuichi Kaneko; Yasuni Nakanuma
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

8.  Chronic cholestasis detection by a novel tool: automated analysis of cytokeratin 7-stained liver specimens.

Authors:  Martti Färkkilä; Johanna Arola; Nelli Sjöblom; Sonja Boyd; Anniina Manninen; Anna Knuuttila; Sami Blom
Journal:  Diagn Pathol       Date:  2021-05-06       Impact factor: 2.644

Review 9.  Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis.

Authors:  Samantha Sarcognato; Diana Sacchi; Federica Grillo; Nora Cazzagon; Luca Fabris; Massimiliano Cadamuro; Ivana Cataldo; Claudia Covelli; Alessandra Mangia; Maria Guido
Journal:  Pathologica       Date:  2021-06

Review 10.  Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.

Authors:  Palak J Trivedi; Christophe Corpechot; Albert Pares; Gideon M Hirschfield
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.